サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1300999

mRNA治療薬の受託開発・製造市場規模、シェア、動向分析レポート：用途別、適応症別、最終用途別、地域別、セグメント予測、2023年～2030年

mRNA Therapeutics Contract Development & Manufacturing Market Size, Share & Trends Analysis Report By Application (Viral Vaccines, Protein Replacement Therapies), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
mRNA治療薬の受託開発・製造市場規模、シェア、動向分析レポート：用途別、適応症別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年06月06日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

mRNA治療薬の受託開発・製造市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のmRNA治療薬の受託開発・製造市場は2030年までに83億5,000万米ドルに達すると予測されています。

同市場は2023年から2030年にかけてCAGR 10.5％で拡大すると予測されています。mRNA技術と細胞送達システムの進歩は、その費用対効果、製造の簡便さ、以前は治療不可能だった経路を標的とする能力と相まって、医療に革命をもたらす無限の可能性を秘めており、mRNA治療薬の受託開発・製造（CDMO）市場に有利な成長機会をもたらしています。

mRNA治療薬開発のための研究開発投資の増加と強力な製品パイプラインも、市場の成長を後押ししています。例えば、米国国立医学図書館のデータベースによると、2021年夏の時点で、mRNAを含む1,800以上の臨床研究が米国でリストアップされており、そのうち約4分の1が第II相試験でした。候補の60％近くは固形がんを対象としており、30％はワクチンです。残りのものは、自己免疫疾患、大腸がん、ライム病などの治療に使用されています。さらに、mRNAは非ウイルス性遺伝子治療デリバリー法の可能性も研究されています。

さらに、未充足の医療ニーズに対応するための新規治療薬の開拓が、製品の市場を変化させています。研究・製造サービスにおける深い知識と、新規分子フォーマットの持続可能な発現とスケールアップを可能にする技術へのニーズは、分子の複雑性の増加によって高まっています。バイオコンジュゲーションや二重特異性抗体の作製などのプラットフォーム技術は、開発・生産期間を大幅に短縮することが可能であり、顧客は、市場投入までの期間を短縮し、投資リスクを軽減することができる熟練したCDMOを求めています。その結果、製薬・バイオテクノロジー業界向けの商品を設計・製造するCDMOへのニーズは飛躍的に高まっています。

2020年のCOVID-19パンデミックを阻止するためのmRNAワクチン接種のイントロダクションと普及により、mRNA技術プラットフォームは画期的な進歩を遂げました。2021年10月に発表された調査論文によると、2019年末時点で、mRNAプラットフォームを専門とする上場企業5社の時価総額の合計は50億米ドルだっています。その時価総額は2021年8月時点で3,000億米ドルを超えています。その結果、COVID-19の発生がmRNAの需要を増大させたことを示しています。

mRNA治療薬の受託開発・製造市場レポートハイライト

  • 感染症分野が市場を独占し、2022年には100%の収益シェアを占める。
  • 代謝・遺伝性疾患分野は、がん治療薬の研究中の強力なパイプラインの存在により、CAGR 11.65%で最大成長が予測されます。
  • ウイルスワクチン分野は2022年に市場を席巻し、ウイルス感染症治療用の各種ワクチンが発売されたことから、売上シェア100%に貢献（COVID-19）。
  • がん免疫療法は、がん治療のための製品開発への注目が高まっていること、および臨床試験でmRNAが良好な結果を示したことから、予測期間中に最大の成長が見込まれます。
  • パンデミック制圧のためのCOVID-19ワクチン上市に向けたバイオテクノロジー企業の精力的な取り組みにより、2022年の市場シェアは62.56%とバイオテクノロジー企業が最も高いです。
  • 政府・学術研究機関セグメントは、mRNAの需要を支える臨床研究件数の増加により、予測期間中に10.81%のCAGRを記録すると予想されています。
  • アジア太平洋地域では、予測期間中にCAGR 9.1%という最速の成長率を記録すると予想されます。インドや中国のような発展途上国では、製薬会社や製造受託機関の数が非常に増加しているため、アジア太平洋地域は近い将来、欧州や北米を追い抜く可能性が高いです。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
  • 市場の定義
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 二次情報と第三者の視点
    • 1次調査
    • 1次調査の詳細
  • 情報分析
    • データ分析モデル
  • 市場の形成とデータの視覚化
    • 商品フロー分析
  • データの検証と公開
  • 世界市場のCAGR計算
  • 二次情報のリスト
  • 一次情報のリスト

第2章 エグゼクティブサマリー

  • 市場スナップショット
  • セグメントスナップショット
  • 競合考察のスナップショット

第3章 市場変数、動向、および範囲

  • 市場の系統
    • 親市場分析
    • 補助的な市場分析
  • mRNA治療薬の受託開発・製造（CDMO）市場- 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境ツール分析mRNA治療薬の受託開発・製造（CDMO）市場
    • ポーターのファイブフォース分析
    • PESTLE分析
  • COVID-19感染症の影響分析

第4章 mRNA治療薬の受託開発・製造（CDMO）市場、用途別の推定・動向分析

  • mRNA治療薬の受託開発・製造（CDMO）市場、用途別の重要なポイント
  • mRNA治療薬の受託開発・製造（CDMO）市場、用途別の動きと市場シェア分析、2022年および2030年
  • ウイルスワクチン
    • ウイルスワクチン開発市場の推計・予測、2020年から2030年（100万米ドル）
  • タンパク質補充療法
    • タンパク質補充療法市場の推計・予測、2020年から2030年（100万米ドル）
  • がん免疫療法
    • がん免疫療法の市場推計・予測、2020年から2030年（100万米ドル）

第5章 mRNA治療薬の受託開発・製造（CDMO）市場の適応症の推定・動向分析

  • mRNA治療薬の受託開発・製造（CDMO）市場、適応症別の重要なポイント
  • mRNA治療薬の受託開発・製造（CDMO）市場、動向および市場シェア分析、2022年および2030年
  • 感染症
    • 感染症市場推計・予測、2020年から2030年（100万米ドル）
  • 代謝疾患と遺伝病
    • 代謝および遺伝病市場推計・予測、2020年から2030年（100万米ドル）
  • 心血管疾患および脳血管疾患
    • 心血管疾患および脳血管疾患市場推計・予測、2020年から2030年（100万米ドル）

第6章 mRNA治療薬の受託開発・製造（CDMO）市場の最終用途の推定・動向分析

  • mRNA治療薬の受託開発・製造（CDMO）市場、最終用途別の重要なポイント
  • mRNA治療薬の受託開発・製造（CDMO）市場、最終用途別向と市場シェア分析、2022年および2030年
  • バイオテクノロジー企業
    • 革新的な市場推計・予測、2020～2030年（100万米ドル）
  • 製薬会社
    • 製薬会社の市場推計・予測、2020-2030（100万米ドル）
  • 政府および学術調査機関
    • 政府および学術調査機関の市場推計・予測、2020年から2030年（100万米ドル）

第7章 mRNA治療薬の受託開発・製造（CDMO）市場の地域分析

  • mRNA治療薬の受託開発・製造（CDMO）の地域市場シェア分析、2022年および2030年
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • チリ
  • MEA
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 会社の分類
  • 戦略マッピング
  • 企業プロファイル・一覧表
    • Danaher（Aldevron）
    • Recipharm AB
    • Biomay AG
    • Samsung Biologics
    • Lonza
    • Catalent , Inc.
    • Bio-Indication Inc,
    • eTheRNA
    • Kaneka Eurogentec SA
    • TriLink BioTechnologies
    • ApexBio Technology
    • BioNTech SE.
    • Biocina
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 4 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 5 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 6 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by region, 2020 - 2030 (USD Million)
  • Table 7 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 8 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 9 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 10 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 11 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 12 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 13 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 14 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020-2030, (USD million
  • Table 15 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 16 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 17 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 18 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 19 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 20 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 21 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 22 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 23 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 24 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 25 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 26 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 27 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 28 France mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 29 France mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 30 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 31 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 32 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 33 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 34 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 35 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 36 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 37 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 38 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 39 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 40 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 41 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 42 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 43 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 44 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 45 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 46 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 47 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 48 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 49 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 50 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 51 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 52 China mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 53 China mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 54 China mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 55 India mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 56 India mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 57 India mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 58 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 59 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 60 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 61 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 62 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 63 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 64 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 65 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 66 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 67 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 68 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 69 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 70 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 71 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 72 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 74 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 76 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 78 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 79 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 80 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 81 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 82 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 83 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 84 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 85 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 86 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 87 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 88 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 89 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 90 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 91 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 92 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 93 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 94 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 95 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 96 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)

List of Figures

  • Fig. 1 mRNA therapeutics contract development and manufacturing (CDMO) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 mRNA Therapeutics Contract Development and Manufacturing (CDMO) - Industry value chain analysis
  • Fig. 15 mRNA therapeutics contract development and manufacturing (CDMO) market driver analysis
  • Fig. 16 mRNA therapeutics contract development and manufacturing (CDMO) market restraint analysis
  • Fig. 17 mRNA therapeutics contract development and manufacturing (CDMO) market: Porter's analysis
  • Fig. 18 mRNA therapeutics contract development and manufacturing (CDMO) market: PESTLE analysis
  • Fig. 19 mRNA therapeutics contract development and manufacturing (CDMO) market: application outlook and key takeaways
  • Fig. 20 mRNA therapeutics contract development and manufacturing (CDMO) market: application market share analysis, 2022 - 2030
  • Fig. 21 Global viral vaccines development market, 2020 - 2030 (USD Million)
  • Fig. 22 Global protein replacement therapies market, 2020 - 2030 (USD Million)
  • Fig. 23 Global cancer immunotherapies market, 2020 - 2030 (USD Million)
  • Fig. 24 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication outlook and key takeaways
  • Fig. 25 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication market share analysis, 2022 - 2030
  • Fig. 26 Global infectious diseases market, 2020 - 2030 (USD Million)
  • Fig. 27 Global metabolic & genetic diseases market, 2020 - 2030 (USD Million)
  • Fig. 28 Global cardiovascular and cerebrovascular diseases market, 2020 - 2030 (USD Million)
  • Fig. 29 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user outlook and key takeaways
  • Fig. 30 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user market share analysis, 2022 - 2030
  • Fig. 31 Global biotech companies market, 2020 - 2030 (USD Million)
  • Fig. 32 Global pharmaceutical companies market, 2020 - 2030 (USD Million)
  • Fig. 33 Global government & academic research institutes market, 2020 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, 2020 - 2030 (USD Million)
  • Fig. 41 Europe mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 42 Germany key country dynamics
  • Fig. 43 Germany mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 46 France key country dynamics
  • Fig. 47 France mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 48 Italy key country dynamics
  • Fig. 49 Italy mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 50 Spain key country dynamics
  • Fig. 51 Spain mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 52 Denmark key country dynamics
  • Fig. 53 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 54 Sweden key country dynamics
  • Fig. 55 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 56 Norway key country dynamics
  • Fig. 57 Norway mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 58 Asia-Pacific mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 59 Japan key country dynamics
  • Fig. 60 Japan mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 65 Australia key country dynamics
  • Fig. 66 Australia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 71 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 72 Brazil key country dynamics
  • Fig. 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 74 Mexico key country dynamics
  • Fig. 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 78 MEA mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 87 Key company categorization
  • Fig. 88 Company market positioning
  • Fig. 89 Market participant categorization
  • Fig. 90 Strategy framework
目次
Product Code: GVR-4-68040-083-7

mRNA Therapeutics Contract Development & Manufacturing Market Growth & Trends

The global mRNA therapeutics contract development and manufacturing market is expected to reach USD 8.35 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.5% from 2023 to 2030. Advances in mRNA technologies and cellular delivery systems coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways have limitless potential that could revolutionize medicine, representing lucrative growth opportunities for the mRNA therapeutics contract development and manufacturing (CDMO) market.

Increasing investments in R&D for the development of mRNA therapeutics and a strong product pipeline are also propelling the growth of the market. For instance, according to the U.S. National Library of Medicine database, as of summer 2021, over 1,800 clinical studies involving mRNA were listed in the U.S. Approximately one-quarter of which were in phase II. Nearly 60% of candidates target solid tumors, while 30% of candidates are vaccines. The remaining ones are used to treat conditions like autoimmune disorders, colorectal cancer, and Lyme disease. Additionally, mRNA is being researched as a possible nonviral gene therapy delivery method.

In addition, the development of novel therapeutics to address unmet medical needs is altering the market for products. The need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats, is being driven by the rise in molecular complexity. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

With the introduction and widespread usage of mRNA vaccinations to stop the COVID-19 pandemic in 2020, mRNA technology platforms had a breakthrough. At the end of 2019, the combined market capitalization of the five publicly listed firms that specialize in mRNA platforms was USD 5 billion, according to a research paper released in October 2021. That capitalization exceeded USD 300 billion as of August 2021. Consequently, indicating that the COVID-19 outbreak has increased the demand for mRNA.

mRNA Therapeutics Contract Development & Manufacturing Market Report Highlights

  • The infectious diseases segment dominated the market and accounted for the entire revenue share of 100% in 2022, due to the launch of various COVID-19 vaccines that primarily used mRNA
  • The metabolic and genetic diseases segment is anticipated to undergo maximum growth with a CAGR of 11.65%, due to the presence of a strong pipeline under research for cancer therapeutics
  • Viral vaccines segment dominated the market in 2022 and contributed towards the entire revenue share of 100% owing to the availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • Cancer immunotherapies is expected to experience maximum growth over the forecast period due to increased focus to develop products for the treatment of cancer and favorable results presented by mRNA for the same in clinical trials
  • Biotech companies held the highest market share of 62.56% in 2022 due to vigorous efforts by these companies to launch COVID-19 vaccines to control the pandemic
  • The Government & Academic Research Institutes segment is anticipated to witness the fastest CAGR of 10.81% over the forecast owing to the rise in the number of clinical research supporting the demand for mRNA
  • In Asia Pacific, the market is expected to register the fastest growth rate of 9.1% CAGR over the forecast period. Due to the extremely rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
      • 1.5.1.1. Approach 1 Commodity flow approach
      • 1.5.1.2. Approach 2 Country wise market estimation using bottom up approach
  • 1.6. Data Validation & Publishing
  • 1.7. Global Market CAGR Calculation
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market - Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High adoption of mRNA in vaccines
      • 3.2.1.2. High number of researches in mRNA therapeutics
      • 3.2.1.3. Fundings for mRNA researches
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of research
      • 3.2.2.2. Availability of substitute therapy at low cost.
  • 3.3. Business Environmental Tools Analysis mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Estimates & Trend Analysis

  • 4.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Application Key Takeaways
  • 4.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viral Vaccines
    • 4.3.1. Viral Vaccines Development Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.4. Protein Replacement Therapies
    • 4.4.1. Protein Replacement Therapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.5. Cancer Immunotherapies
    • 4.5.1. Cancer Immunotherapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 5. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Estimates & Trend Analysis

  • 5.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Indication Key Takeaways
  • 5.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Infectious Diseases
    • 5.3.1. Infectious Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.4. Metabolic & Genetic Diseases
    • 5.4.1. Metabolic & Genetic Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.5. Cardiovascular & Cerebrovascular Diseases
    • 5.5.1. Cardiovascular & Cerebrovascular Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 6. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Estimates & Trend Analysis

  • 6.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By End Use Key Takeaways
  • 6.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Biotech Companies
    • 6.3.1. Innovative Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.4. Pharmaceutical companies
    • 6.4.1. Pharmaceutical companies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.5. Government & Academic Research Institutes
    • 6.5.1. Government & Academic Research Institutes Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 7. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Regional Analysis

  • 7.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Regional market share analysis, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Market estimates and forecast, 2020 - 2030
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Market estimates and forecast, 2020 - 2030
    • 7.2.3. Canada
      • 7.2.3.1. Canada Market estimates and forecast, 2020 - 2030
  • 7.3. Europe
    • 7.3.1. Europe Market estimates and forecast, 2020 - 2030
    • 7.3.2. UK
      • 7.3.2.1. UK Market estimates and forecast, 2020 - 2030
    • 7.3.3. Germany
      • 7.3.3.1. Germany Market estimates and forecast, 2020 - 2030
    • 7.3.4. France
      • 7.3.4.1. France Market estimates and forecast, 2020 - 2030
    • 7.3.5. Italy
      • 7.3.5.1. Italy Market estimates and forecast, 2020 - 2030
    • 7.3.6. Spain
      • 7.3.6.1. Spain Market estimates and forecast, 2020 - 2030
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Market estimates and forecast, 2020 - 2030
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Market estimates and forecast, 2020 - 2030
    • 7.3.9. Norway
      • 7.3.9.1. Norway Market estimates and forecast, 2020 - 2030
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Market estimates and forecast, 2020 - 2030
    • 7.4.2. Japan
      • 7.4.2.1. Japan Market estimates and forecast, 2020 - 2030
    • 7.4.3. China
      • 7.4.3.1. China Market estimates and forecast, 2020 - 2030
    • 7.4.4. India
      • 7.4.4.1. India Market estimates and forecast, 2020 - 2030
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Market estimates and forecast, 2020 - 2030
    • 7.4.6. Australia
      • 7.4.6.1. Australia Market estimates and forecast, 2020 - 2030
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Market estimates and forecast, 2020 - 2030
    • 7.4.8. South Korea
      • 7.4.8.1. South Korea Market estimates and forecast, 2020 - 2030
  • 7.5. Latin America
    • 7.5.1. Latin America Market estimates and forecast, 2020 - 2030
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Market estimates and forecast, 2020 - 2030
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Market estimates and forecast, 2020 - 2030
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Market estimates and forecast, 2020 - 2030
    • 7.5.5. Colombia
      • 7.5.5.1. Colombia Market estimates and forecast, 2020 - 2030
    • 7.5.6. Chile
      • 7.5.6.1. Chile Market estimates and forecast, 2020 - 2030
  • 7.6. MEA
    • 7.6.1. MEA Market estimates and forecast, 2020 - 2030
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Market estimates and forecast, 2020 - 2030
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Market estimates and forecast, 2020 - 2030
    • 7.6.4. UAE
      • 7.6.4.1. UAE Market estimates and forecast, 2020 - 2030
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Market estimates and forecast, 2020 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Danaher (Aldevron)
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Recipharm AB
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Biomay AG
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Samsung Biologics
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Lonza
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Catalent , Inc.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Bio-Indication Inc,
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. eTheRNA
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Kaneka Eurogentec S.A
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. TriLink BioTechnologies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. ApexBio Technology
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. BioNTech SE.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Biocina
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives